MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 407965 | Name: FM19G11
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FM19G11 is an inhibitor of Hypoxia Inducible Factors α (HIFα), reported to affect self-renewal and differentiation of stem cells. Hypoxia-inducible factors (HIFs) are transcription factors that respond to changes in available oxygen in the cellular environment. Among other functions (like angiogenesis), HIFα proteins affect the self-renewal and the differentiation processes of stem cells. FM19G11 inhibits the HIFα proteins that repress the target genes of the two α subunits, in various tumor cell lines as well as in adult and embryonic stem cell (ESC) models.

Chemical Structure

FM19G11
FM19G11
CAS#329932-55-0

Theoretical Analysis

MedKoo Cat#: 407965

Name: FM19G11

CAS#: 329932-55-0

Chemical Formula: C23H17N3O8

Exact Mass: 463.1016

Molecular Weight: 463.40

Elemental Analysis: C, 59.61; H, 3.70; N, 9.07; O, 27.62

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
FM19G11; FM19-G11; FM19 G11; FM19G11; FM 19G11; FM-19G11; HIF-1alpha/2alpha Inhibitor; HIF Inhibitor IV
IUPAC/Chemical Name
[2-oxo-2-(p-tolyl)ethyl] 3-[(2,4-dinitrobenzoyl)amino]benzoate
InChi Key
XVUOIWIIQVGWAJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H17N3O8/c1-14-5-7-15(8-6-14)21(27)13-34-23(29)16-3-2-4-17(11-16)24-22(28)19-10-9-18(25(30)31)12-20(19)26(32)33/h2-12H,13H2,1H3,(H,24,28)
SMILES Code
O=C(OCC(C1=CC=C(C)C=C1)=O)C2=CC=CC(NC(C3=CC=C([N+]([O-])=O)C=C3[N+]([O-])=O)=O)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells.
In vitro activity:
After FM19G11 treatment (300 nmol/L for 3 days), MGMT expression was significantly suppressed in both cell lines (Figures 1 and 2). Reference: Cancer Med. 2018 Jul; 7(7): 3292–3300. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051152/
In vivo activity:
The increase in HOMA-IR was reduced to 1.70 ± 0.42 after 7 days of i.p. administration of FM19G11 (10 mg·kg−1·day−1) (P < 0.05 vs. untreated fructose-fed rats). Administration of FM19G11 completely reversed the impairment in endothelial vasodilatation, as ACh-induced responses in aortic segments from IRR treated with FM19G11 were not significantly different from those obtained in aortae from CRs (Figure 1A). Reference: Br J Pharmacol. 2015 Mar; 172(5): 1277–1291. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337701/
Solvent mg/mL mM
Solubility
DMSO 46.3 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 463.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. You CG, Sheng HS, Xie CR, Zhang N, Zheng XS. FM19G11 inhibits O6 -methylguanine DNA-methyltransferase expression under both hypoxic and normoxic conditions. Cancer Med. 2018 May 15;7(7):3292–300. doi: 10.1002/cam4.1551. Epub ahead of print. PMID: 29761922; PMCID: PMC6051152. 2. Rodríguez-Jiménez FJ, Moreno-Manzano V, Mateos-Gregorio P, Royo I, Erceg S, Murguia JR, Sánchez-Puelles JM. FM19G11: A new modulator of HIF that links mTOR activation with the DNA damage checkpoint pathways. Cell Cycle. 2010 Jul 15;9(14):2803-13. doi: 10.4161/cc.9.14.12184. Epub 2010 Jul 3. PMID: 20676050. 3. 1. El Assar M, Sánchez-Puelles JM, Royo I, López-Hernández E, Sánchez-Ferrer A, Aceña JL, Rodríguez-Mañas L, Angulo J. FM19G11 reverses endothelial dysfunction in rat and human arteries through stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α activation. Br J Pharmacol. 2015 Mar;172(5):1277-91. doi: 10.1111/bph.12993. Epub 2015 Jan 12. PMID: 25363469; PMCID: PMC4337701.
In vitro protocol:
1. You CG, Sheng HS, Xie CR, Zhang N, Zheng XS. FM19G11 inhibits O6 -methylguanine DNA-methyltransferase expression under both hypoxic and normoxic conditions. Cancer Med. 2018 May 15;7(7):3292–300. doi: 10.1002/cam4.1551. Epub ahead of print. PMID: 29761922; PMCID: PMC6051152. 2. Rodríguez-Jiménez FJ, Moreno-Manzano V, Mateos-Gregorio P, Royo I, Erceg S, Murguia JR, Sánchez-Puelles JM. FM19G11: A new modulator of HIF that links mTOR activation with the DNA damage checkpoint pathways. Cell Cycle. 2010 Jul 15;9(14):2803-13. doi: 10.4161/cc.9.14.12184. Epub 2010 Jul 3. PMID: 20676050.
In vivo protocol:
1. El Assar M, Sánchez-Puelles JM, Royo I, López-Hernández E, Sánchez-Ferrer A, Aceña JL, Rodríguez-Mañas L, Angulo J. FM19G11 reverses endothelial dysfunction in rat and human arteries through stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α activation. Br J Pharmacol. 2015 Mar;172(5):1277-91. doi: 10.1111/bph.12993. Epub 2015 Jan 12. PMID: 25363469; PMCID: PMC4337701. 2. Rodríguez-Jimnez FJ, Alastrue-Agudo A, Erceg S, Stojkovic M, Moreno-Manzano V. FM19G11 favors spinal cord injury regeneration and stem cell self-renewal by mitochondrial uncoupling and glucose metabolism induction. Stem Cells. 2012 Oct;30(10):2221-33. doi: 10.1002/stem.1189. PMID: 22865656.
1: You CG, Sheng HS, Xie CR, Zhang N, Zheng XS. FM19G11 inhibits O(6) -methylguanine DNA-methyltransferase expression under both hypoxic and normoxic conditions. Cancer Med. 2018 May 15. doi: 10.1002/cam4.1551. [Epub ahead of print] PubMed PMID: 29761922; PubMed Central PMCID: PMC6051152. 2: Alastrue-Agudo A, Rodriguez-Jimenez FJ, Mocholi EL, De Giorgio F, Erceg S, Moreno-Manzano V. FM19G11 and Ependymal Progenitor/Stem Cell Combinatory Treatment Enhances Neuronal Preservation and Oligodendrogenesis after Severe Spinal Cord Injury. Int J Mol Sci. 2018 Jan 9;19(1). pii: E200. doi: 10.3390/ijms19010200. PubMed PMID: 29315225; PubMed Central PMCID: PMC5796149. 3: Ruzaeva VA, Morgun AV, Khilazheva ED, Kuvacheva NV, Pozhilenkova EA, Boitsova EB, Martynova GP, Taranushenko TE, Salmina AB. [Development of blood-brain barrier under the modulation of HIF activity in astroglialand neuronal cells in vitro]. Biomed Khim. 2016 Nov;62(6):664-669. doi: 10.18097/PBMC20166206664. Russian. PubMed PMID: 28026810. 4: Zhang F, Duan S, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y. Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer. Cancer Sci. 2016 Jun;107(6):746-54. doi: 10.1111/cas.12937. Epub 2016 May 3. PubMed PMID: 27009878; PubMed Central PMCID: PMC4968604. 5: Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S, Jögi A. HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells. Oncotarget. 2016 Mar 8;7(10):11238-50. doi: 10.18632/oncotarget.7167. PubMed PMID: 26849233; PubMed Central PMCID: PMC4905469. 6: El Assar M, Sánchez-Puelles JM, Royo I, López-Hernández E, Sánchez-Ferrer A, Aceña JL, Rodríguez-Mañas L, Angulo J. FM19G11 reverses endothelial dysfunction in rat and human arteries through stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α activation. Br J Pharmacol. 2015 Mar;172(5):1277-91. doi: 10.1111/bph.12993. Epub 2015 Jan 12. PubMed PMID: 25363469; PubMed Central PMCID: PMC4337701. 7: Marampon F, Gravina GL, Zani BM, Popov VM, Fratticci A, Cerasani M, Di Genova D, Mancini M, Ciccarelli C, Ficorella C, Di Cesare E, Festuccia C. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay. Int J Oncol. 2014 Jun;44(6):2121-31. doi: 10.3892/ijo.2014.2358. Epub 2014 Mar 24. PubMed PMID: 24676782. 8: Yang X, Yang ZJ, Liu FX, Zeng K, Qian MQ, Chen G, Shi L, Zhu GX. Inhibition of mTOR and HIF pathways diminishes chondro-osteogenesis and cell proliferation in chondroblastoma. Tumour Biol. 2013 Oct;34(5):3111-9. doi: 10.1007/s13277-013-0879-8. Epub 2013 Jun 13. PubMed PMID: 23760978. 9: Valdes-Sánchez T, Rodriguez-Jimenez FJ, García-Cruz DM, Escobar-Ivirico JL, Alastrue-Agudo A, Erceg S, Monleón M, Moreno-Manzano V. Methacrylate-endcapped caprolactone and FM19G11 provide a proper niche for spinal cord-derived neural cells. J Tissue Eng Regen Med. 2015 Jun;9(6):734-9. doi: 10.1002/term.1735. Epub 2013 Mar 27. PubMed PMID: 23533014. 10: Rodríguez-Jimnez FJ, Alastrue-Agudo A, Erceg S, Stojkovic M, Moreno-Manzano V. FM19G11 favors spinal cord injury regeneration and stem cell self-renewal by mitochondrial uncoupling and glucose metabolism induction. Stem Cells. 2012 Oct;30(10):2221-33. doi: 10.1002/stem.1189. PubMed PMID: 22865656. 11: Rodríguez-Jiménez FJ, Moreno-Manzano V, Mateos-Gregorio P, Royo I, Erceg S, Murguia JR, Sánchez-Puelles JM. FM19G11: A new modulator of HIF that links mTOR activation with the DNA damage checkpoint pathways. Cell Cycle. 2010 Jul 15;9(14):2803-13. Epub 2010 Jul 3. PubMed PMID: 20676050. 12: Moreno-Manzano V, Rodríguez-Jiménez FJ, Aceña-Bonilla JL, Fustero-Lardíes S, Erceg S, Dopazo J, Montaner D, Stojkovic M, Sánchez-Puelles JM. FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem. 2010 Jan 8;285(2):1333-42. doi: 10.1074/jbc.M109.008326. Epub 2009 Nov 6. PubMed PMID: 19897487; PubMed Central PMCID: PMC2801260.